Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia

Clicks: 417
ID: 117237
1998
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Respiratory syncytial virus (RSV) causes serious respiratory illness in preterm children with bronchopulmonary dysplasia. In a prospective randomized placebo-controlled trial, 21 children received one dose of PFP-2 (purified fusion [F] protein) vaccine or influenza vaccine (placebo). Children were f …
Reference Key
jr1998thesafety Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Groothuis JR;King SJ;Hogerman DA;Paradiso PR;Simoes EA;;
Journal The Journal of infectious diseases
Year 1998
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/9466539
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't u.s. gov't Child Infant Prospective Studies newborn P.H.S. preschool Clinical Trial Randomized Controlled Trial Antibodies Double-Blind Method Viral / analysis neutralization tests respiratory syncytial virus infections / prevention & control* viral vaccines / adverse effects* hospitalization viral / immunology hn protein* viral envelope proteins seasons respiratory syncytial virus infections / immunology* immunoglobulin g / analysis immunoglobulin g / immunology viral proteins / immunology* viral vaccines / immunology* viral vaccines / administration & dosage pmid:9466539 doi:10.1086/517377 j r groothuis s j king e a simoes bronchopulmonary dysplasia / virology* influenza vaccines / administration & dosage influenza vaccines / adverse effects influenza vaccines / immunology

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.